WO2021096217A1 - 재조합 안정화 갈렉틴 9 단백질을 포함하는 류마티스 관절염 및 골질환 예방 또는 치료용 약학적 조성물 - Google Patents
재조합 안정화 갈렉틴 9 단백질을 포함하는 류마티스 관절염 및 골질환 예방 또는 치료용 약학적 조성물 Download PDFInfo
- Publication number
- WO2021096217A1 WO2021096217A1 PCT/KR2020/015782 KR2020015782W WO2021096217A1 WO 2021096217 A1 WO2021096217 A1 WO 2021096217A1 KR 2020015782 W KR2020015782 W KR 2020015782W WO 2021096217 A1 WO2021096217 A1 WO 2021096217A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- recombinant
- pharmaceutical composition
- preventing
- bone disease
- Prior art date
Links
- 101710121810 Galectin-9 Proteins 0.000 title claims abstract description 70
- 102100031351 Galectin-9 Human genes 0.000 title claims abstract description 69
- 208000020084 Bone disease Diseases 0.000 title claims abstract description 47
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 26
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 13
- 230000002265 prevention Effects 0.000 title abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims description 33
- 108091033319 polynucleotide Proteins 0.000 claims description 28
- 102000040430 polynucleotide Human genes 0.000 claims description 28
- 239000002157 polynucleotide Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 230000036541 health Effects 0.000 claims description 17
- 235000013376 functional food Nutrition 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 14
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 210000002437 synoviocyte Anatomy 0.000 claims description 14
- 208000006386 Bone Resorption Diseases 0.000 claims description 13
- 208000001132 Osteoporosis Diseases 0.000 claims description 12
- 210000000447 Th1 cell Anatomy 0.000 claims description 12
- 210000000068 Th17 cell Anatomy 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 11
- 210000000988 bone and bone Anatomy 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 230000024245 cell differentiation Effects 0.000 claims description 9
- 206010065687 Bone loss Diseases 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 3
- 208000027868 Paget disease Diseases 0.000 claims description 3
- 206010052306 Periprosthetic osteolysis Diseases 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 230000034994 death Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000027202 mammary Paget disease Diseases 0.000 claims description 3
- 208000030016 Avascular necrosis Diseases 0.000 claims description 2
- 208000017701 Endocrine disease Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 2
- 208000002804 Osteochondritis Diseases 0.000 claims description 2
- 201000009859 Osteochondrosis Diseases 0.000 claims description 2
- 208000003076 Osteolysis Diseases 0.000 claims description 2
- 206010031264 Osteonecrosis Diseases 0.000 claims description 2
- 206010049088 Osteopenia Diseases 0.000 claims description 2
- 230000008482 dysregulation Effects 0.000 claims description 2
- 208000030172 endocrine system disease Diseases 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 2
- 230000005499 meniscus Effects 0.000 claims description 2
- 230000030991 negative regulation of bone resorption Effects 0.000 claims description 2
- 230000020395 negative regulation of osteoclast differentiation Effects 0.000 claims description 2
- 208000005368 osteomalacia Diseases 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 208000007442 rickets Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 206010061223 Ligament injury Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 31
- 239000000203 mixture Substances 0.000 abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 6
- 210000004899 c-terminal region Anatomy 0.000 abstract description 5
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 26
- 230000002401 inhibitory effect Effects 0.000 description 22
- 210000002997 osteoclast Anatomy 0.000 description 21
- 230000004069 differentiation Effects 0.000 description 19
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 230000024279 bone resorption Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 229940122361 Bisphosphonate Drugs 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 150000004663 bisphosphonates Chemical class 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000007563 Galectins Human genes 0.000 description 2
- 108010046569 Galectins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- -1 and the like Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108010049264 Teriparatide Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a recombinant stabilized galectin 9 protein and its use, and specifically relates to a pharmaceutical composition for preventing or treating bone diseases including rheumatoid arthritis comprising the protein as an active ingredient.
- Galectin 9 one of the tandem repeat-type galectins, consists of two sugar chain recognition sites (sugar recognition domain, carbohydrate recognition domain: CRD) and a link peptide region connecting them, and the N-terminal domain (N -terminal Carbohydrate Recognition Domain; NCRD) and C-terminal Carbohydrate Recognition Domain (CCRD) are linked, and various activities have been reported to date.
- galectin 9 binds to Tim-3, induces apoptosis of Tim-3 positive Th1 cells, and suppresses autoimmune inflammation by inhibiting excessive Th1 response. In addition, it reduces Th17 cells, one of the causes or exacerbations of various intractable diseases such as autoimmune diseases, allergies and cancers expressed by Tim-3.
- galectin 9 enhances immunity in some cases. It binds to Tim-3 on monocytes or dendritic cells to activate the cells and promote the production of inflammatory cytokines. In addition, the interaction of galectin 9 and Tim-3 in macrophages enhances immunity to exclude Mycobacterium tuberculosis.
- bone is a dynamic tissue that undergoes continuous removal and reconstruction through bone resorption and formation.
- This process is carried out by two types of cells: osteoclast and osteoblast, respectively.
- osteoblasts are responsible for bone formation
- osteoclasts are responsible for bone removal.
- bone homeostasis is maintained by the balanced activity of the two cells.
- homeostasis can be stopped due to abnormal hyperactivity of these two types of cells, especially osteoclasts, resulting in arthritis, osteoporosis, periprosthetic osteolysis and Paget's disease. disease). Therefore, precise control of the differentiation and function of osteoclasts is important in the prevention and treatment of bone diseases.
- a drug therapy for treating osteoporosis it is a drug that promotes bone formation or inhibits bone resorption to prevent a decrease in the amount of bone or to increase the amount of bone.
- a bone resorption inhibitor calcium preparations, vitamin D preparations, bisphosphonate preparations (bisphosphonate), an estrogen agonist/antagonist, an estrogen agent, and an injection of teriparatide, a parathyroid hormone agent, as an stimulator of bone formation.
- rheumatoid arthritis is a typical chronic autoimmune disease, which is caused by inflammation of the synovial tissue surrounding the joint. It can occur in all joints where synovial membranes exist, and it is a chronic inflammatory disease that invades various organs throughout the body, causing severe joint disorders and premature death by destroying joint tissue. In some severe patients, tissues other than joints, such as the lungs, heart, eyes, gastrointestinal tract, skin and kidneys, can be affected, although rare. Moreover, inflammatory mediators, which are generally secreted in large amounts in the body, adversely affect bone metabolism, increasing the risk of osteoporosis and fracture. In fact, the incidence of osteoporosis in rheumatoid arthritis patients is confirmed to be about 15 to 20%.
- Drug therapy to treat rheumatoid arthritis includes first-line drugs such as non-steroidal anti-inflammatory drugs, steroid drugs, which are hormones, and second-line drugs that inhibit rheumatoid arthritis itself by affecting the body's immune system. Need to be careful about. In particular, in the case of steroid preparations, when they are used, they feel good immediately and are abused, but the side effects are serious. It can also be a risk factor for osteoporosis when taken for a long time.
- first-line drugs such as non-steroidal anti-inflammatory drugs, steroid drugs, which are hormones
- second-line drugs that inhibit rheumatoid arthritis itself by affecting the body's immune system. Need to be careful about. In particular, in the case of steroid preparations, when they are used, they feel good immediately and are abused, but the side effects are serious. It can also be a risk factor for osteoporosis when taken for a long time.
- the present inventors have tried to develop a new therapeutic agent that has an effective therapeutic effect while minimizing the side effects of arthritis and/or osteoporosis therapeutic agents including rheumatoid arthritis.
- the C-terminal domain of the two sugar chain recognition sites of the existing wild-type galectin 9 (CCRD) and a recombinant stabilized galectin 9 protein in which amino acids of link peptides are deleted and substituted inhibit Th1 and Th17 differentiation, and induce apoptosis of fibroblast-like synoviocytes (FLS),
- FLS fibroblast-like synoviocytes
- An object of the present invention is to provide a recombinant stabilized galectin 9 protein and a pharmaceutical composition for preventing or treating bone diseases comprising the same.
- the present invention provides a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1.
- the present invention provides a recombinant vector comprising a gene encoding the protein.
- the present invention provides a transformant into which the recombinant vector has been inserted.
- the present invention comprises a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 or a polynucleotide encoding the same as an active ingredient, a pharmaceutical composition for preventing or treating bone disease;
- a method for treating bone diseases comprising administering to an individual a pharmaceutically effective amount of a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 or a polynucleotide encoding the same;
- a pharmaceutical composition comprising a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 for use in the prevention or treatment of bone diseases or a polynucleotide encoding the same;
- it provides the use of a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 or a polynucleotide encoding the same for the manufacture of a pharmaceutical composition for preventing or treating bone disease.
- the present invention is a health functional food for preventing or improving bone disease, comprising a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 as an active ingredient;
- a method for preventing or improving bone disease comprising administering to an individual a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 or a polynucleotide encoding the same in a pharmaceutically effective amount;
- Health functional food comprising a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 for use in preventing or improving bone disease or a polynucleotide encoding the same;
- it provides the use of a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 or a polynucleotide encoding the same for the manufacture of a health functional food for preventing or improving bone disease.
- the recombinant stabilized galectin 9 protein of the present invention exhibits the effect of inhibiting Th1 and Th17 cell differentiation, killing synovial cells (FLS, Fibroblast-like synoviocytes), and inhibiting osteoclast differentiation, so that bone diseases including rheumatoid arthritis It can be usefully used as an active ingredient of a composition for prevention or treatment.
- FIG. 1 is a diagram confirming the degree of binding of Tim-3 of the recombinant stabilized galectin 9 protein (sGal-9) according to the present invention.
- Figure 2 is a diagram confirming the effect of inhibiting Th1 and Th17 cell differentiation of sGal-9 according to the present invention.
- FIG. 3 is a diagram illustrating the apoptosis effect of sGal-9 according to the present invention on FLS (Fibroblast-like synoviocytes; synovial cells).
- Figure 4 is a diagram confirming the effect of inhibiting osteoclast differentiation of sGal-9 according to the present invention.
- FIG. 5 is a diagram illustrating the effect of inhibiting bone resorption of sGal-9 according to the present invention.
- the present invention provides a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1.
- the recombinant stabilized galectin 9 protein has a more stable molecular structure against proteases while maintaining the sugar chain recognition activity of wild type Galectin-9.
- the recombinant stabilized galectin 9 protein is a link region connecting two CRDs (Carbohydrate Recognition Domains) of wild-type galectin 9 having a structure of NCRD-linker-CCRD and a C-terminal Carbohydrate Recognition Domain (CCRD); C-terminal domain ) Is a recombinant protein produced by modifying.
- CRD Carbohydrate Recognition Domains
- the recombinant stabilized galectin 9 protein has all of the peptides of the linker region deleted, the amino acid sequence at positions 1 to 10 (SEQ ID NO: 3) in CCRD (SEQ ID NO: 2) is deleted, and Ala at position 13 (Alarine; A) is substituted with Pro (Proline; P) and may consist of an amino acid sequence represented by SEQ ID NO: 1, and 75% or more, preferably 80% or more, more preferably, with the amino acid sequence represented by SEQ ID NO: 1 May comprise an amino acid sequence having sequence homology of 90% or more, most preferably 95% or more, and prepared for a specific purpose to increase targeting sequence, tag, labeled residue, half-life or peptide stability. An amino acid sequence may additionally be included.
- the recombinant protein of the present invention can be obtained by various methods well known in the art. As an example, it may be prepared using a polynucleotide recombination and protein expression system, or synthesized in vitro through chemical synthesis such as peptide synthesis, and a cell-free protein synthesis method.
- polynucleotide is a polymer to which nucleotides are bound, and serves to transmit genetic information.
- the term "homology" used in the present invention is intended to indicate a degree of similarity with a wild-type amino acid sequence or a polynucleotide sequence, and comparison of such homology can be performed using a comparison program well known in the art, 2 The homology between two or more sequences can be calculated as a percentage (%).
- the present invention provides a recombinant vector comprising a gene encoding the protein.
- the present invention provides a transformant into which the recombinant vector has been inserted.
- vector refers to a plasmid, virus, or other medium known in the art into which a gene or a base sequence can be inserted or introduced, specifically, a linear DNA plasmid DNA, a recombinant non-viral vector, or a recombinant virus. It may be a sex vector or an inducible gene expression vector system, and the recombinant viral vector is a retrovirus, adenovirus, adeno-associated virus, helper-dependent adenovirus, herpes simplex virus, lentiviral vector, or It may be a vaccinia virus, but is not limited thereto.
- the nucleotide sequence according to the present invention may be operably linked to an expression control sequence, and the operably linked nucleotide sequence may be included in one expression vector including a selection marker and a replication origin.
- the “operably linked” may be a gene and an expression control sequence linked in a manner that allows gene expression when an appropriate molecule is bound to the expression control sequence.
- “Expression control sequence” refers to a DNA sequence that controls the expression of a nucleotide sequence operably linked in a specific host cell.
- Such regulatory sequences include promoters for carrying out transcription, any operator sequences for regulating transcription, sequences encoding suitable mRNA ribosome binding sites, and sequences controlling termination of transcription and translation.
- transformation used in the present invention means that the genetic properties of an organism are changed by a given DNA from the outside, that is, DNA, which is a type of nucleic acid extracted from a cell of a certain lineage, is introduced into living cells of another lineage. It means a phenomenon in which DNA enters the cell and changes its genotype.
- the cell may be a prokaryotic cell or a eukaryotic cell, but is not limited thereto.
- the gene encoding the recombinant protein is prepared from a known sequence as described above, and a primer that can specifically recognize it is prepared, and using this, through a polymerase chain reaction (PCR).
- the gene can be amplified and introduced into a cell after introducing it into a vector as described above.
- Methods of introduction are known and include, for example, liposome-mediated transduction, calcium phosphate method, DEAE-dextran-mediated translocation, positively charged lipid mediated translocation, electroporation, transduction using a phage system, or infection using a virus. Including, but not limited to.
- the present invention provides a pharmaceutical composition for preventing or treating bone diseases, comprising a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 or a polynucleotide encoding the same as an active ingredient.
- prevention refers to any action that suppresses the onset or delays the onset by administration of the composition.
- treatment refers to any action in which the symptoms of the disease are improved or beneficially changed by the administration of the composition.
- the recombinant stabilized galectin 9 protein exhibits any one or more of the following properties, and thus may have an effect of preventing or treating bone diseases:
- the recombinant stabilized galectin 9 protein can inhibit helper T cells such as Th1 and Th17 through a mechanism of inducing apoptosis by binding with the Tim-3 protein expressed in T cells.
- helper T cells such as Th1 and Th17
- the synovial cells are one of the important pathologies of rheumatoid arthritis along with inflammatory cytokines, and as the disease progresses, abnormal proliferation and activation of synovial cells is a problem, so that inflammation and destruction of joints may continue to occur.
- the recombinant stabilized galectin 9 protein secretes MMP (matrix methalloproteinase) and cathepsin to destroy the matrix of articular cartilage, fibroblast-like synoviocytes. Can be destroyed.
- MMP matrix methalloproteinase
- the recombinant stabilized galectin 9 protein may inhibit osteoclast differentiation and bone resorption.
- the osteoclast is a multinuclear cell that destroys and absorbs bone tissue that is unnecessary in bone growth, and when the balance with osteoblasts involved in bone regeneration and regeneration is disrupted, osteoporosis may occur, causing bone loss.
- the bone resorption (bone resorption) is a phenomenon in which bone is absorbed by the activity of bone-destructive cells, and bisphosphonate, a generally known osteoporosis drug, inhibits the bone resorption and prevents osteoporosis from worsening.
- the bone diseases are arthritis, osteoporosis, periprosthetic osteolysis, osteolysis due to fatigue remnants of implants, Paget's disease, osteomalacia, rickets, osteopenia, calcium dysregulation, metastatic Bone cancer (metastatic bone cancer), inflammatory bone loss, endocrine disease or secondary bone loss (secondary bone loss) caused by drugs or periodontal disease accompanied by destruction of alveolar bone, but is not limited thereto.
- the arthritis may be osteoarthritis, degenerative arthritis, rheumatoid arthritis, detachable osteochondritis, joint ligament damage, meniscus damage, joint misalignment, avascular necrosis, or juvenile idiopathic arthritis, but is not limited thereto.
- the present inventors use a chromatography method after dissolving and purifying E. coli cells that induced the expression of a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1
- a recombinant protein was prepared.
- the recombinant protein exhibited the effect of inhibiting Th1 and Th17 cell differentiation, the effect of killing fibroblast-like synoviocytes (FLS), and the inhibitory effect of osteoclast differentiation. Therefore, the recombinant protein and the polynucleotide encoding the same can be usefully used as an active ingredient in a composition for preventing or treating bone diseases.
- the recombinant protein of the present invention or the polynucleotide encoding the same can be transported in a pharmaceutically acceptable carrier such as colloidal suspension, powder, saline, lipids, liposomes, microspheres, or nano-spherical particles. . They can be complexed or associated with the vehicle and are known in the art such as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation reagents, polysaccharides, polyamino acids, dendrimers, saponins, adsorption enhancing substances or fatty acids. It can be delivered in vivo using known delivery systems.
- a pharmaceutically acceptable carrier such as colloidal suspension, powder, saline, lipids, liposomes, microspheres, or nano-spherical particles.
- pharmaceutically acceptable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, which are commonly used in formulation.
- a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like may be additionally included in addition to the above components.
- the pharmaceutical composition of the present invention can be administered orally or parenterally (for example, intramuscular, intravenous, intraperitoneal, subcutaneous, intradermal, or topically applied) according to a desired method, and the dosage is It depends on the condition and weight, the degree of the disease, the form of the drug, the route of administration and the time, but may be appropriately selected by a person skilled in the art.
- the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
- the term "pharmaceutically effective amount” refers to an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type, severity, and drug of the patient's disease. Activity, sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field.
- the pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent, or may be used in combination with surgery, hormone therapy, drug treatment, and biological response modifier, and may be administered simultaneously, separately or sequentially with the agent, single or It can be administered multiple times. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all of the above factors, and this can be easily determined by a person skilled in the art.
- the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, condition, weight, absorption of the active ingredient in the body, inactivation rate, excretion rate, type of disease, and drugs used in combination, and the route of administration, Obesity may increase or decrease depending on the severity, sex, weight, and age.
- the present invention provides a health functional food for preventing or improving bone diseases, comprising a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 as an active ingredient.
- the contents of the recombinant stabilized galectin 9 protein and bone disease are the same as those described above, and the detailed descriptions refer to the above.
- the term “improvement” refers to any action that at least reduces the severity of a parameter related to the condition being treated, for example, symptoms.
- the health functional food composition may be used before or after the onset stage of the disease in order to prevent or improve bone disease, and simultaneously with or separately from the drug for treatment.
- the recombinant stabilized galectin 9 protein having the amino acid sequence represented by SEQ ID NO: 1 inhibits Th1 and Th17 cell differentiation, fibroblast-like-synoviocytes (FLS) killing effect and osteoclasts. Since it was confirmed that the (osteoclast) differentiation inhibitory effect was shown, the recombinant protein can be usefully used as an active ingredient of a health functional food for preventing or improving bone disease.
- the active ingredient may be added to the food as it is or may be used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
- the mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (for prevention or improvement).
- the health functional food of the present invention may be added in an amount of preferably 15% by weight or less, preferably 10% by weight or less based on the raw material.
- the amount may be less than the above range.
- the health functional food of the present invention may contain other ingredients as essential ingredients without particular limitation in addition to containing the active ingredient.
- various flavoring agents or natural carbohydrates may be included as additional ingredients.
- natural carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, and the like; And polysaccharides, for example, common sugars such as dextrin, cyclodextrin, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- natural flavoring agents taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)
- synthetic flavoring agents sacharin, aspartame, etc.
- I can.
- the proportion of the natural carbohydrate can be appropriately determined by the choice of a person skilled in the art.
- the health functional food of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavoring agents, coloring agents and heavy weight agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid. And salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like. These components may be used independently or in combination, and the proportion of these additives may also be appropriately selected by those skilled in the art.
- the present invention provides a method for preventing or treating bone diseases comprising administering to an individual a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 or a polynucleotide encoding the same in a pharmaceutically effective amount. do.
- the present invention provides a method for preventing or improving bone disease, comprising administering to an individual a pharmaceutically effective amount of a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 or a polynucleotide encoding the same. do.
- Recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 of the present invention or a polynucleotide encoding the same has a synergistic effect of Tim-3 protein binding, an effect of inhibiting Th1 and Th17 cell differentiation, an effect of inhibiting the help of T cells, fiber A cell-like-synovial cell killing effect, an osteoclast differentiation inhibitory effect, and a bone resorption inhibitory effect are shown, and thus, it can be usefully used to treat bone diseases.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 or a polynucleotide encoding the same for use in the prevention or treatment of bone disease.
- the present invention provides a health functional food comprising a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 or a polynucleotide encoding the same for use in preventing or improving bone disease.
- the present invention provides a use of a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 or a polynucleotide encoding the same for the manufacture of a pharmaceutical composition for preventing or treating bone disease.
- the present invention provides a use of a recombinant stabilized galectin 9 protein having an amino acid sequence represented by SEQ ID NO: 1 or a polynucleotide encoding the same for the manufacture of a health functional food for preventing or improving bone disease.
- An expression vector containing a gene encoding a recombinant stabilized galectin 9 protein having an amino acid sequence of SEQ ID NO: 1 was prepared, and the expression vector was introduced into E. coli by a heat shock method. Expression of the recombinant protein was carried out by culturing E. coli in an LB medium containing 50 ⁇ g/ml kanamycin, adding arabinose when the absorbance at 600 nm reached 0.7 to induce expression of the recombinant protein.
- the cells inducing the expression of the recombinant protein were lysed and filtered, and the target protein was captured using a cation exchange method and an affinity column to obtain a highly purified recombinant stabilized galectin 9 protein in high yield.
- Recombinant human Tim-3 (R&D systems, Cat. No. 10241-TI-050) at a concentration of 0.5 ⁇ g/ml was added 100 ⁇ l to each well of a 96-well ELISA plate (Nunc, Cat. No. 44-2404-21). After adding and reacting overnight at room temperature, it was washed three times with DPBS (Dulbecco's phosphate-buffered saline; Welgene, Cat. No. LB011-02) containing 0.05% of Tween 20 (Sigma Cat. No. P9416).
- DPBS Dynabecco's phosphate-buffered saline
- Welgene Cat. No. LB011-02
- Tween 20 Sigma Cat. No. P9416
- DPBS containing 1% bovine serum albumin (BSA) was added to each well, incubated for 1 hour at room temperature, and washed three times with a wash buffer.
- BSA bovine serum albumin
- the recombinant stabilized galectin 9 protein (sGal-9) obtained in ⁇ Preparation Example 1> was diluted to various concentrations (0, 5, 10 and 20 ⁇ g/ml), and 100 ⁇ l each was added to each well at room temperature. After incubation for 2 hours at, it was washed 3 times with a washing buffer.
- Gal-9 antibody (R&D systems, Cat. No. 1015238) was diluted 1:1000 with 1% BSA/DPBS, added 100 ⁇ l to each well, and incubated for 1 hour at room temperature, and then used as a washing buffer. Washed twice.
- anti-mouse HRP antibody (Invitrogen, Cat. No. 31430) was diluted 1:1000 with 1% BSA/DPBS, added to each well, and incubated for 1 hour at room temperature for 1 hour. Washed twice.
- Anti-CD3 (eBioscience, Cat. No. 16-0031-82) with a concentration of 2 ⁇ g/ml diluted with PBS (Welgene, Cat. No. LB 001-02) was added 100 ⁇ l each to a 96-well plate or 24 wells. After dispensing 500 ⁇ l of each plate and reacting overnight at 4° C., it was washed once with PBS and used for cell culture.
- IFN- ⁇ cells of Th1 cells and IL-17 cytokines of Th17 cells were measured according to the manufacturer's procedure using an ELISA assay kit (Mouse DuoSet, R&D Systems).
- FLS cells (cell passage: RA_FLS 2-92#P7) were dispensed into each well of a 48-well plate (SPL, Cat. 100 ⁇ l of sGal-9 at concentrations (2.5, 5, and 10 ⁇ g/ml) was added to each well. After 16 hours, the supernatant was collected and stored in a deep freezer.
- FACS fluorescence-activated cell sorting
- Osteoclasts were passaged 1 ml each at a cell density of 2.5 x 105 cells/ml in each well of a 12-well plate (Corning, Cat. No. 3513), and after 24 hours, various concentrations (0.1, 0.5, 1, 2, 4, and 10 ⁇ g/ml) of sGal-9 and 1 ml of PBS were added to each well as a control group.
- the stained osteoclasts of the experimental group and the control group were stained with TRAP using a TRAP Staining Kit (K-ASSAY, Cat. No. KT-008) and counted using an optical microscope, and then three or more nuclei were observed.
- the resulting multinuclear cells (TRAP(+) MNCs) were judged to have differentiated into osteoclasts.
- osteoclast cells are placed in each well. Passage 1 ml each at a cell density of 2.5 x 105 cells/ml, and after 24 hours, each well with sGal-9 and PBS as a control group as an experimental group of various concentrations (0.1, 0.5, 1, 2, 4 and 10 ⁇ g/ml) 1 ml was added to each.
- the experimental group (sGal-9), the control group (PBS), and the cell culture solution (MEM-alpha, gibco, Cat. No. 12561-056) were replaced daily until the differentiation was completed.
- sGal-9 increased the Tim-3 protein binding ability in a concentration-dependent manner, inhibited Th1 and Th17 cell differentiation, and increased synovial cell death effect, and osteoclast differentiation. It was confirmed that bone diseases can be prevented or treated by increasing the inhibitory effect and bone resorption inhibitory effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (18)
- 서열번호 1로 표시되는 아미노산 서열을 가지는 재조합 안정화 갈렉틴 9 단백질.
- 제 1항에 있어서, 상기 재조합 안정화 갈렉틴 9 단백질은 야생형 갈렉틴 9의 당쇄 인식 활성을 유지하는 것을 특징으로 하는, 재조합 안정화 갈렉틴 9 단백질.
- 제 1항의 단백질을 암호화하는 유전자를 포함하는, 재조합 벡터.
- 제 3항의 재조합 벡터가 삽입된, 형질전환체.
- 서열번호 1로 표시되는 아미노산 서열을 가지는 재조합 안정화 갈렉틴 9 단백질 또는 이를 암호화하는 폴리뉴클레오타이드를 유효성분으로 포함하는, 골질환 예방 또는 치료용 약학적 조성물.
- 제 5항에 있어서, 상기 재조합 안정화 갈렉틴 9 단백질은 다음 중 어느 하나 이상의 특성을 나타내는 것을 특징으로 하는, 골질환 예방 또는 치료용 약학적 조성물:i) Tim-3 단백질 결합도 상승;ii) Th1 및 Th17 세포 분화 억제;iii) 도움 T세포(T helper cell) 억제;iv) 섬유아세포-유사-활막세포(FLS, Fibroblast-like synoviocytes) 사멸; 및v) 파골세포(osteoclast) 분화 및 뼈흡수 억제.
- 제 5항에 있어서, 상기 골질환은 관절염, 골다공증, 인공관절 주위 골용해(periprosthetic osteolysis), 임플란트의 피로잔해에 의한 골용해, 파제트병(Paget's disease), 골연화증, 구루병, 골감소증, 칼슘조절이상, 전이성 골암(metastatic bone cancer), 염증성 골소실, 내분비 질환 또는 약물에 의한 이차성 골손실(secondary bone loss) 및 치조골의 파괴가 동반되는 치주질환으로 이루어진 군으로부터 선택되는 어느 하나 이상인 것을 특징으로 하는, 골질환 예방 또는 치료용 약학적 조성물.
- 제 7항에 있어서, 상기 관절염은 골관절염, 퇴행성 관절염, 류마티스 관절염, 박리성 골연골염, 관절 인대손상, 반월상 연골판 손상, 관절의 부정정렬, 무혈성 괴사증, 및 소아 특발성 관절염으로 이루어진 군으로부터 선택되는 것을 특징으로 하는, 골질환 예방 또는 치료용 약학적 조성물.
- 제 5항에 있어서, 상기 골질환은 류마티스 관절염 또는 골다공증인 것을 특징으로 하는, 골질환 예방 또는 치료용 약학적 조성물.
- 제 5항에 있어서, 상기 약학적 조성물은 약학적으로 허용 가능한 담체를 더 포함하는 것을 특징으로 하는, 골질환 예방 또는 치료용 약학적 조성물.
- 제 5항에 있어서, 상기 약학적 조성물은 경구 투여용, 근육내 투여용, 정맥내 투여용, 복강내 투여용, 피하 투여용, 피내 투여용, 또는 국소 투여용으로 제제화되는 것을 특징으로 하는, 골질환 예방 또는 치료용 약학적 조성물.
- 서열번호 1로 표시되는 아미노산 서열을 가지는 재조합 안정화 갈렉틴 9 단백질을 유효성분으로 포함하는, 골질환 예방 또는 개선용 건강기능식품.
- 서열번호 1로 표시되는 아미노산 서열을 가지는 재조합 안정화 갈렉틴 9 단백질 또는 이를 암호화하는 폴리뉴클레오타이드를 약학적으로 유효한 양으로 개체에 투여하는 단계를 포함하는 골질환 치료방법.
- 서열번호 1로 표시되는 아미노산 서열을 가지는 재조합 안정화 갈렉틴 9 단백질 또는 이를 암호화하는 폴리뉴클레오타이드를 약학적으로 유효한 양으로 개체에 투여하는 단계를 포함하는 골질환 예방 또는 개선방법.
- 골질환 예방 또는 치료에 사용하기 위한 서열번호 1로 표시되는 아미노산 서열을 가지는 재조합 안정화 갈렉틴 9 단백질 또는 이를 암호화하는 폴리뉴클레오타이드를 포함하는 약학적 조성물.
- 골질환 예방 또는 개선에 사용하기 위한 서열번호 1로 표시되는 아미노산 서열을 가지는 재조합 안정화 갈렉틴 9 단백질 또는 이를 암호화하는 폴리뉴클레오타이드를 포함하는 건강기능식품.
- 골질환을 예방 또는 치료하는 약학적 조성물의 제조를 위한 서열번호 1로 표시되는 아미노산 서열을 가지는 재조합 안정화 갈렉틴 9 단백질 또는 이를 암호화하는 폴리뉴클레오타이드의 용도.
- 골질환을 예방 또는 개선하는 건강기능식품의 제조를 위한 서열번호 1로 표시되는 아미노산 서열을 가지는 재조합 안정화 갈렉틴 9 단백질 또는 이를 암호화하는 폴리뉴클레오타이드의 용도.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/763,902 US20220372088A1 (en) | 2019-11-11 | 2020-11-11 | Pharmaceutical composition, comprising recombinant stabilized galectin 9 protein, for prevention or treatment of rheumatoid arthritis and bone disease |
BR112022005782A BR112022005782A2 (pt) | 2019-11-11 | 2020-11-11 | Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante |
JP2022516730A JP7468930B2 (ja) | 2019-11-11 | 2020-11-11 | 組換え安定化ガレクチン9タンパク質を含む関節リウマチ及び骨疾患予防または治療用薬学的組成物 |
AU2020384824A AU2020384824A1 (en) | 2019-11-11 | 2020-11-11 | Pharmaceutical composition, comprising recombinant stabilized galectin 9 protein, for prevention or treatment of rheumatoid arthritis and bone disease |
MX2022003598A MX2022003598A (es) | 2019-11-11 | 2020-11-11 | Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas. |
CA3157954A CA3157954A1 (en) | 2019-11-11 | 2020-11-11 | Pharmaceutical composition, comprising recombinant stabilized galectin 9 protein, for prevention or treatment of rheumatoid arthritis and bone disease |
CN202080077890.XA CN115605217A (zh) | 2019-11-11 | 2020-11-11 | 包含重组稳定半乳糖凝集素9蛋白的用于预防或治疗类风湿关节炎及骨病的药物组合物 |
EP20887590.6A EP4059511A4 (en) | 2019-11-11 | 2020-11-11 | PHARMACEUTICAL COMPOSITION, COMPRISING A RECOMBINANT STABILIZED GALECTIN 9 PROTEIN, FOR THE PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS AND BONE DISEASE |
JP2024006967A JP2024041993A (ja) | 2019-11-11 | 2024-01-19 | 組換え安定化ガレクチン9タンパク質を含む関節リウマチ及び骨疾患予防または治療用薬学的組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190143752 | 2019-11-11 | ||
KR10-2019-0143752 | 2019-11-11 | ||
KR10-2020-0149295 | 2020-11-10 | ||
KR1020200149295A KR102267413B1 (ko) | 2019-11-11 | 2020-11-10 | 재조합 안정화 갈렉틴 9 단백질을 포함하는 류마티스 관절염 및 골질환 예방 또는 치료용 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021096217A1 true WO2021096217A1 (ko) | 2021-05-20 |
Family
ID=75912133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/015782 WO2021096217A1 (ko) | 2019-11-11 | 2020-11-11 | 재조합 안정화 갈렉틴 9 단백질을 포함하는 류마티스 관절염 및 골질환 예방 또는 치료용 약학적 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220372088A1 (ko) |
EP (1) | EP4059511A4 (ko) |
JP (2) | JP7468930B2 (ko) |
AU (1) | AU2020384824A1 (ko) |
MX (1) | MX2022003598A (ko) |
WO (1) | WO2021096217A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024049227A1 (ko) * | 2022-08-31 | 2024-03-07 | (주)지바이오로직스 | 재조합 안정화 갈렉틴 9 단백질을 포함하는 루푸스 예방 또는 치료용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003189874A (ja) * | 2001-12-28 | 2003-07-08 | Galpharma Co Ltd | ガレクチン−9活性制御剤 |
KR20070031887A (ko) * | 2004-03-29 | 2007-03-20 | 가르파마 컴퍼니 리미티드 | 신규 갈렉틴 9 개변체 단백질 및 그 용도 |
JP2012515766A (ja) * | 2009-01-26 | 2012-07-12 | 国立大学法人 岡山大学 | 免疫抑制剤および自己免疫疾患の予防および治療剤 |
US20150307574A1 (en) * | 2012-11-20 | 2015-10-29 | National University Corporation Kagawa University | Modified galectin-9 protein |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007291022A (ja) * | 2006-04-26 | 2007-11-08 | Galpharma Co Ltd | 軟骨分化促進作用 |
KR20130103587A (ko) * | 2010-12-09 | 2013-09-23 | 가르파마 컴퍼니 리미티드 | 갈렉틴 9를 분비하는 세포, 그 제조 방법 및 그 용도 |
-
2020
- 2020-11-11 EP EP20887590.6A patent/EP4059511A4/en active Pending
- 2020-11-11 AU AU2020384824A patent/AU2020384824A1/en active Pending
- 2020-11-11 WO PCT/KR2020/015782 patent/WO2021096217A1/ko unknown
- 2020-11-11 US US17/763,902 patent/US20220372088A1/en active Pending
- 2020-11-11 JP JP2022516730A patent/JP7468930B2/ja active Active
- 2020-11-11 MX MX2022003598A patent/MX2022003598A/es unknown
-
2024
- 2024-01-19 JP JP2024006967A patent/JP2024041993A/ja not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003189874A (ja) * | 2001-12-28 | 2003-07-08 | Galpharma Co Ltd | ガレクチン−9活性制御剤 |
KR20070031887A (ko) * | 2004-03-29 | 2007-03-20 | 가르파마 컴퍼니 리미티드 | 신규 갈렉틴 9 개변체 단백질 및 그 용도 |
JP2012515766A (ja) * | 2009-01-26 | 2012-07-12 | 国立大学法人 岡山大学 | 免疫抑制剤および自己免疫疾患の予防および治療剤 |
US20150307574A1 (en) * | 2012-11-20 | 2015-10-29 | National University Corporation Kagawa University | Modified galectin-9 protein |
Non-Patent Citations (2)
Title |
---|
See also references of EP4059511A4 * |
SEKI, M. OOMIZU, S. SAKATA, K.M. SAKATA, A. ARIKAWA, T. WATANABE, K. ITO, K. TAKESHITA, K. NIKI, T. SAITA, N. : "Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis", CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 127, no. 1, 20 February 2008 (2008-02-20), AMSTERDAM, NL, pages 78 - 88, XP022535315, ISSN: 1521-6616, DOI: 10.1016/j.clim.2008.01.006 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024049227A1 (ko) * | 2022-08-31 | 2024-03-07 | (주)지바이오로직스 | 재조합 안정화 갈렉틴 9 단백질을 포함하는 루푸스 예방 또는 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
JP2022548279A (ja) | 2022-11-17 |
JP2024041993A (ja) | 2024-03-27 |
AU2020384824A1 (en) | 2022-04-14 |
JP7468930B2 (ja) | 2024-04-16 |
US20220372088A1 (en) | 2022-11-24 |
EP4059511A1 (en) | 2022-09-21 |
MX2022003598A (es) | 2022-06-08 |
EP4059511A4 (en) | 2024-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2210354T3 (es) | Factor de necrosis tumoral humano delta y epsilon. | |
Reichert et al. | Interleukin 6 in intact and injured mouse peripheral nerves | |
BR112020009920A2 (pt) | Agonistas parciais de interleucina-2 | |
JP2007314575A (ja) | 治療剤としてのプロサポシンおよびサイトカイン由来ペプチド | |
JP2001522239A (ja) | 87個のヒト分泌タンパク質 | |
US8071716B2 (en) | Thymus-specific protein | |
UA70283C2 (en) | Peptide (variants), a pharmaceutical composition cpeptide (variants), a pharmaceutical composition composed of peptide and a method for the preparatioomposed of peptide and a method for the preparation thereof (variants) n thereof (variants) | |
KR20150022800A (ko) | 악액질 예방 또는 치료용 조성물 | |
JP2001521383A (ja) | 20個のヒト分泌タンパク質 | |
WO2021096217A1 (ko) | 재조합 안정화 갈렉틴 9 단백질을 포함하는 류마티스 관절염 및 골질환 예방 또는 치료용 약학적 조성물 | |
JP4932731B2 (ja) | シグナルペプチド、核酸分子及び治療方法 | |
KR101723786B1 (ko) | Il―21을 발현하는 중간엽 줄기세포를 포함하는 b 세포 림프종 예방 또는 치료용 조성물 | |
CN110869386A (zh) | 重组神经生长因子的组合物和方法 | |
WO2012002762A2 (ko) | 알러지성 질환의 치료 및 예방을 위한 펩타이드 | |
KR102267413B1 (ko) | 재조합 안정화 갈렉틴 9 단백질을 포함하는 류마티스 관절염 및 골질환 예방 또는 치료용 약학적 조성물 | |
KR101950035B1 (ko) | 세포투과성을 갖는 r12 -pias3 융합 펩타이드 및 이를 유효성분으로 함유하는 면역질환의 예방 또는 치료용 조성물 | |
HU218947B (hu) | Metabolikus csontbetegség kezelésére szolgáló humán Il-1R proteint tartalmazó gyógyszerkészítmények | |
US6809175B1 (en) | Cadherin derived growth factor and its use | |
WO2022080865A9 (ko) | 반려견의 항암용 재조합 단백질 및 이를 포함하는 반려견을 위한 항암용 조성물 | |
KR102671044B1 (ko) | 아커만시아 뮤시니필라 유래의 tars 또는 이의 단편 및 이의 용도 | |
WO2023080553A1 (ko) | 생리 활성을 갖는 펩타이드 및 그의 용도 | |
WO2023080552A1 (ko) | 생리 활성을 갖는 펩타이드 및 그의 용도 | |
US20220347264A1 (en) | Use of fkbp-l polypeptides and nucleic acids for the treatment of obesity | |
US20040171122A1 (en) | Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same | |
KR100636017B1 (ko) | 전사 활성화제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20887590 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022516730 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022005782 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020384824 Country of ref document: AU Date of ref document: 20201111 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3157954 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020887590 Country of ref document: EP Effective date: 20220613 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112022005782 Country of ref document: BR Free format text: 1) ESCLARECER, EM ATE 60 (SESSENTA) DIAS, A EXCLUSAO DA PRIORIDADE KR 10-2020-0149295 DE 10/11/2020 QUE CONSTA NA PUBLICACAO INTERNACIONAL WO/2021/096217 DE 20/05/2021, DO FORMULARIO DA PETICAO INICIAL NO 870220026092 DE 25/03/2022 E APRESENTAR A DOCUMENTACAO REFERENTE A MESMA. 2) COM BASE NA PORTARIA 56 DE 27/12/2021, SOLICITA-SE QUE SEJA APRESENTADO, EM ATE 60 (SESSENTA) DIAS, NOVO CONTEUDO DE LISTAGEM DE SEQUENCIA POIS O CONTEUDO APRESENTADO NA PETICAO NO 870220027078 DE 29/03/2022 POSSUI INFORMACOES DIVERGENTES ENTRE O INFORMADO NO CAMPO 150 / 151 E O CONSTANTE NO WO/2021/096217 DE 20/05/2021. |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01Y Ref document number: 112022005782 Country of ref document: BR Free format text: ANULADA A PUBLICACAO CODIGO 1.5 NA RPI NO 2685 DE 21/06/2022 POR TER SIDO INDEVIDA. |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112022005782 Country of ref document: BR Free format text: COM BASE NA PORTARIA 48 DE 20/06/2022, SOLICITA-SE QUE SEJA APRESENTADO, EM ATE 60 (SESSENTA) DIAS, NOVO CONTEUDO DE LISTAGEM DE SEQUENCIA COM BASE NA PORTARIA 56 DE 27/12/2021, POIS O CONTEUDO APRESENTADO NA PETICAO NO 870220027078 DE 29/03/2022 POSSUI INFORMACOES DIVERGENTES ENTRE O INFORMADO NO CAMPO 150 / 151 E O CONSTANTE NO WO/2021/096217 DE 20/05/2021. |
|
ENP | Entry into the national phase |
Ref document number: 112022005782 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220325 |